Search Results: spinraza
New Spinraza Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with SMA
Biogen, Inc. announced new interim results from NURTURE, an ongoing open-label, single-arm efficacy and safety study of SPINRAZA® (nusinersen) in 25 presymptomatic infants with SMA. […]
Read More ›Biogen Releases Community Statement on Spinraza Access and New Data
Biogen has released the following community statement on Spinraza access and new research data. Dear Members of the SMA community, Thank you for your continued […]
Read More ›The Discovery of Spinraza
SMA is caused by a mutation in the survival motor neuron gene 1 (SMN1). In a healthy person, this gene produces a protein—called survival motor […]
Read More ›Biogen Issues Community Update on Spinraza
Biogen has provided the following community statement on Spinraza. Dear Members of the SMA community, As part of our commitment to the SMA community to […]
Read More ›Recording of the September Webinar on Spinraza Updates Now Available
A recording of last week’s webinar updating the community on Spinraza access and administration sites is now available online. A PDF of the webinar presentation is also […]
Read More ›Cure SMA to Host Webinar Updating the Community on Spinraza Access
On Tuesday, September 19, at 12:00pm CST (10:00am PST/11:00am MST/1:00pm EST), Cure SMA will hold a webinar updating the community on the status of Spinraza […]
Read More ›Biogen Releases Update on Spinraza Access
On Monday, Biogen released an update detailing our community’s progress in gaining access to Spinraza. The latest update shows that significant progress has been made […]
Read More ›Anthem Updates Insurance Policy for Spinraza
Anthem Inc. recently announced an updated insurance policy for the use of Spinraza (nusinersen) for treatment of spinal muscular atrophy. The revised policy expands criteria […]
Read More ›European Commission Grants Marketing Authorization for Spinraza, Making it First Approved SMA Treatment in the European Union
Biogen announced today that the European Commission (EC) has granted a marketing authorization for Spinraza for the treatment of spinal muscular atrophy (SMA), making it […]
Read More ›Cure SMA to Host Webinar on Spinraza Access, as List of Administration Sites is Released
On Thursday, May 4, at 1:00pm EST (10:00am PST/11:00am MST/12:00pm CST), Cure SMA will hold a webinar updating the community on the status of Spinraza […]
Read More ›